Download PDF
J Pediatr Infect Dis 2018; 13(03): 229-233
DOI: 10.1055/s-0038-1657790
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Mecillinam: Old Molecule, New Option

Fulya Bayındır Bilman
1   Department of Medical Microbiology, İzmir Menemen State Hospital, İzmir, Turkey
,
Mevliye Yetik
1   Department of Medical Microbiology, İzmir Menemen State Hospital, İzmir, Turkey
› Author Affiliations
Further Information

Publication History

14 December 2017

29 April 2018

Publication Date:
23 June 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Mecillinam is a β-lactam antibiotic that is increasingly being used for the treatment of uncomplicated urinary tract infections. Nevertheless, the international guidelines still recommend nitrofurantoin, fosfomycin trometamol, and pivmecillinam as first-line agents in the treatment of such infections.

Aim The objective of this study was to determine the in vitro efficacy of mecillinam against Escherichia coli and Klebsiella pneumoniae strains isolated from children with urinary tract infections.

Materials Methods We investigated E. coli and K. pneumoniae isolates, obtained within the period from January 2016 to October 2017, from urine samples of patients aged 0 to 16 years. Antibiotics susceptibility testing was conducted through the disk diffusion method based on the guidelines provided by EUCAST (European Committee on Antimicrobial Susceptibility Testing). Extended-spectrum β-lactamase (ESBL)-positivity was detected by the double-disk synergy test. Isolates with mecillinam inhibition-zone diameter breakpoints lower than < 15 mm were considered to be resistant according to EUCAST criteria.

Results A total of 450 isolates were assessed in the study, 135 of which were ESBL-producing E.coli, 230 were non-ESBL-producing E. coli, 35 were ESBL-producing K. pneumoniae, and 50 were non-ESBL-producing K. pneumoniae isolates. Mecillinam susceptibility was observed in most of the non-ESBL-producing and ESBL-producing E. coli isolates (230/230, 100% and 115/135, 85.1%, respectively). The rates of susceptibility of the non-ESBL-producing and ESBL-producing K. pneumoniae isolates were 37/50 (74%) and 24/35 (68.6%), respectively.

Conclusion The in vitro susceptibility results obtained support the usage of mecillinam as a first-line agent. The high susceptibility of non-ESBL-producing E. coli and K. pneumoniae isolates established in vitro brings the hope that this antibiotic could soon be used in clinical practice in Turkey.

Keywords

mecillinam - antibiotic susceptibility test - Escherichia coli - Klebsiella pneumoniae
 

  • References

  • 1 Kahlmeter G, Åhman J, Matuschek E. Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect Dis Ther 2015; 4 (04) 417-423
    CrossrefPubMedGoogle Scholar
  • 2 Theuretzbacher U, Van Bambeke F, Cantón R. , et al. Reviving old antibiotics. J Antimicrob Chemother 2015; 70 (08) 2177-2181
    CrossrefPubMedGoogle Scholar
  • 3 Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014; 5 (05) 551
    CrossrefPubMedGoogle Scholar
  • 4 Tybring L. Mecillinam (FL 1060), a 6 beta-amidinopenicillanic acid derivative: in vitro evaluation. Antimicrob Agents Chemother 1975; 8 (03) 266-270
    CrossrefPubMedGoogle Scholar
  • 5 Zhanel GG, Karlowsky JA, Schwartz B, Jensen SB, Hoban DJ. Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli. Chemotherapy 1998; 44 (06) 391-396
    CrossrefPubMedGoogle Scholar
  • 6 Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 2014; 69 (02) 303-308
    CrossrefPubMedGoogle Scholar
  • 7 EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 2.0, July 2017 Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of_resistance_mechanisms_170711.pdf . Accessed November 23, 2017
    PubMed
  • 8 EUCAST. Clinical Breakpoints. Available at: http://www.eucast.org/clinical_breakpoints . Accessed November 23, 2017
    PubMed
  • 9 Wootton M, Walsh TR, Macfarlane L, Howe RA. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010; 65 (01) 79-81
    CrossrefPubMedGoogle Scholar
  • 10 Monsen TJ, Holm SE, Ferry BM, Ferry SA. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women. APMIS 2014; 122 (04) 317-323
    CrossrefPubMedGoogle Scholar
  • 11 Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. Clin Microbiol Infect 2015; 21 (10) 899-905
    CrossrefPubMedGoogle Scholar
  • 12 Sougakoff W, Jarlier V. Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different beta-lactamases. J Antimicrob Chemother 2000; 46 (01) 9-14
    PubMedGoogle Scholar
  • 13 Kresken M, Körber-Irrgang B, Naber KG. In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany [Article in German]. Aktuelle Urol 2017; 48 (03) 243-247
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kranz J, Schmidt S, Lebert C. , et al. Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients: update 2017 of the interdisciplinary AWMF S3 guideline [Article in German]. Urologe A 2017; 56 (06) 746-758
    CrossrefPubMedGoogle Scholar
  • 15 Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgrad Med 2017; 129 (02) 242-258
    CrossrefPubMedGoogle Scholar
  • 16 Lindbäck H, Lindbäck J, Melhus Å. Inadequate adherence to Swedish guidelines for uncomplicated lower urinary tract infections among adults in general practice. APMIS 2017; 125 (09) 816-821
    CrossrefPubMedGoogle Scholar
  • 17 O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland. BMC Infect Dis 2016; 16 (01) 620
    CrossrefPubMedGoogle Scholar
  • 18 Baines SD, O'Connor R, Huscroft G, Saxton K, Freeman J, Wilcox MH. Mecillinam: a low-risk antimicrobial agent for induction of Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2009; 63 (04) 838-839
    CrossrefPubMedGoogle Scholar
  • 19 Sullivan A, Fianu-Jonasson A, Landgren BM, Nord CE. Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. Antimicrob Agents Chemother 2005; 49 (01) 170-175
    CrossrefPubMedGoogle Scholar
  • 20 Fournier D, Chirouze C, Leroy J. , et al. Alternatives to carbapenems in ESBL-producing Escherichia coli infections. Med Mal Infect 2013; 43 (02) 62-66
    CrossrefPubMedGoogle Scholar
  • 21 Zykov IN, Sundsfjord A, Småbrekke L, Samuelsen Ø. The antimicrobial activity of mecillinam, nitrofurantoin, temocillin and fosfomycin and comparative analysis of resistance patterns in a nationwide collection of ESBL-producing Escherichia coli in Norway 2010-2011. Infect Dis (Lond) 2016; 48 (02) 99-107
    CrossrefPubMedGoogle Scholar
  • 22 Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54 (05) 1164-1175
    CrossrefPubMedGoogle Scholar
  • 23 Schito GC, Naber KG, Botto H. , et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34 (05) 407-413
    CrossrefPubMedGoogle Scholar
  • 24 Salomonsson P, von Linstow ML, Knudsen JD. , et al. Best oral empirical treatment for pyelonephritis in children: do we need to differentiate between age and gender?. Infect Dis (Lond) 2016; 48 (10) 721-725
    CrossrefPubMedGoogle Scholar
  • 25 Titelman E, Iversen A, Kalin M, Giske CG. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae . Microb Drug Resist 2012; 18 (02) 189-192
    CrossrefPubMedGoogle Scholar
  • 26 Pinart M, Kranz J, Jensen K. , et al. Optimal dosage and duration of pivmecillinam treatment for uncomplicated lower urinary tract infections: a systematic review and meta-analysis. Int J Infect Dis 2017; 58: 96-109
    CrossrefPubMedGoogle Scholar
  • 27 Thulin E, Thulin M, Andersson DI. Reversion of high-level mecillinam resistance to susceptibility in Escherichia coli during growth in urine. EBioMedicine 2017; 23: 111-118
    CrossrefPubMedGoogle Scholar
  • 28 Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli . Antimicrob Agents Chemother 2010; 54 (09) 4006-4008
    CrossrefPubMedGoogle Scholar
  • 29 Duployez C, Loiez C, Cattoen C, Descamps D, Wallet F, Vachée A. ; Microbiologist Network from Nord-Pas-de-Calais. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women. Med Mal Infect 2016; 46 (08) 436-441
    CrossrefPubMedGoogle Scholar
  • 30 Søraas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS One 2014; 9 (01) e85889
    CrossrefPubMedGoogle Scholar
  • 31 Lampri N, Galani I, Poulakou G. , et al. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli . J Antimicrob Chemother 2012; 67 (10) 2424-2428
    CrossrefPubMedGoogle Scholar
  • 32 Christensen B. Which antibiotics are appropriate for treating bacteriuria in pregnancy?. J Antimicrob Chemother 2000; 46 (01) 29-34
    CrossrefPubMedGoogle Scholar